These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7535978)

  • 21. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM; Rose AL; Higano C
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
    BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Examination of the change in plasma concentration of OH-flutamide in low-dose flutamide (250 mg/day) monotherapy for prostate cancer patients].
    Harano M; Kano M; Hida T; Fujisawa Y; Kano M
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):377-80. PubMed ID: 15045944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.
    Sekido N; Kawai K; Akaza H; Koiso K
    Jpn J Clin Oncol; 1995 Aug; 25(4):164-7. PubMed ID: 7545251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer.
    Berruti A; Dogliotti L; Fasolis G; Mosca A; Tarabuzzi R; Torta M; Mari M; Fontana D; Angeli A
    J Urol; 1999 Jan; 161(1):176-81. PubMed ID: 10037393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
    Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
    Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate specific antigen in the diagnosis and staging of prostate cancer.
    Jung P; Wolff JM; Mattelaer P; Jakse G
    Acta Urol Belg; 1996 Sep; 64(3):1-6. PubMed ID: 8946774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
    Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antiandrogen suppression syndrome in patients with hormone-resistant cancer of the prostate].
    Morote Robles J; Lorente Garín JA; Encabo G
    Actas Urol Esp; 1998 Sep; 22(8):661-5. PubMed ID: 9835085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer.
    Suzuki K; Nishiyama T; Hara N; Yamana K; Takahashi K; Labrie F
    Prostate Cancer Prostatic Dis; 2007; 10(3):301-6. PubMed ID: 17387321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic options in patients with hormone-refractory prostate cancer.
    Anand N
    Am J Med; 1996 Feb; 100(2):243-4. PubMed ID: 8629663
    [No Abstract]   [Full Text] [Related]  

  • 36. Hydroxyflutamide may not always be a pure antiandrogen.
    Yeh S; Miyamoto H; Chang C
    Lancet; 1997 Mar; 349(9055):852-3. PubMed ID: 9121269
    [No Abstract]   [Full Text] [Related]  

  • 37. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy.
    Dupont A; Gomez JL; Cusan L; Koutsilieris M; Labrie F
    J Urol; 1993 Sep; 150(3):908-13. PubMed ID: 7688437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
    Fowler JE; Pandey P; Seaver LE; Feliz TP
    J Urol; 1995 Aug; 154(2 Pt 1):448-53. PubMed ID: 7541862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
    Sartor O; Cooper M; Weinberger M; Headlee D; Thibault A; Tompkins A; Steinberg S; Figg WD; Linehan WM; Myers CE
    J Natl Cancer Inst; 1994 Feb; 86(3):222-7. PubMed ID: 7506794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: Characterization of patients with androgen independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
    Small EJ
    J Urol; 1997 Aug; 158(2):552. PubMed ID: 9224356
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.